<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292186</url>
  </required_header>
  <id_info>
    <org_study_id>ALN-TTRSC-003</org_study_id>
    <nct_id>NCT02292186</nct_id>
  </id_info>
  <brief_title>A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis</brief_title>
  <official_title>A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alnylam Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alnylam Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the safety and clinical activity of long-term
      dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being
      followed-up for safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">February 22, 2017</completion_date>
  <primary_completion_date type="Actual">February 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of long-term dosing with revusiran (ALN-TTRSC) as measured by number of adverse events in patients with transthyretin (TTR) cardiac amyloidosis</measure>
    <time_frame>Up to 35 days post last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes from baseline in serum TTR</measure>
    <time_frame>From Baseline to Day 1372</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>From Baseline to Day 1344</time_frame>
    <description>Total number of deaths in the study and total number of deaths adjudicated as being related to cardiovascular causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of cardiovascular-related and heart failure-related hospitalizations</measure>
    <time_frame>From Baseline to Day 1344</time_frame>
    <description>The number of times that a subject is hospitalized for cardiovascular- or heart failure- related causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test performance</measure>
    <time_frame>From Baseline to Day 1344</time_frame>
    <description>Change from Baseline to Day 1344 in the total distance walked</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>TTR-mediated Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Revusiran (ALN-TTRSC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Revusiran (ALN-TTRSC)</intervention_name>
    <arm_group_label>Revusiran (ALN-TTRSC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who previously received and tolerated revusiran (ALN-TTRSC) in the
             ALN-TTRSC-002 study

          -  Adequate liver function

          -  Not Pregnant or nursing

        Exclusion Criteria:

          -  Inadequate renal function

          -  Uncontrolled hypertension, ischemic heart disease or clinically significant cardiac
             arrhythmia

          -  Untreated hypo- or hyperthyroidism

          -  Prior major organ transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Gollob, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alnylam Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>UK NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiomyopathy</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>FAC</keyword>
  <keyword>Amyloid</keyword>
  <keyword>Transthyretin</keyword>
  <keyword>TTR</keyword>
  <keyword>RNAi therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 22, 2018</submitted>
    <returned>March 19, 2018</returned>
    <submitted>March 27, 2018</submitted>
    <returned>April 25, 2018</returned>
    <submitted>May 16, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

